Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1637 1699
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17760213 | Ribozyme-mediated RNA Assembly and Expression | Final Rejection | University of Rochester |
| 18146818 | COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING INHIBITOR OF ATLASTIN 2, AND METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE BY DETERMINING ATLASTIN 2 | Non-Final OA | Research & Business Foundation Sungkyunkwan University |
| 17937256 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17619633 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy